Niagen Bioscience Q2 Revenue Misses, Profit Collapses as Costs Surge; Launches Pharma Program
NAGE is trading near its 52-week low of $3.115 (3.4% above the low).
Summary
Niagen Bioscience missed Q2 revenue estimates and saw profits collapse as ingredient sales slumped and marketing costs surged. The company also launched a pharmaceutical program and telehealth platform, but the near-term outlook remains pressured.
Updates
· SEC 10-Q — The 10-Q reports net income of $963,000 for Q2 2026, with diluted EPS of $0.01, and cash and cash equivalents of $66.7 million as of June 30, 2026.
Key Events · Earnings and Guidance · NAGE
-
Q2 Revenue Miss
Net sales of $29.8 million missed the $30.7 million consensus, with Tru Niagen sales of $24.2 million and ingredient sales declining to $5.4 million from $7.4 million a year ago.
-
Profit Collapse
Net income fell to $1.0 million from $3.6 million in Q2 2025, driven by a 23% increase in sales and marketing expenses to $10.1 million. Adjusted EBITDA dropped to $3.0 million from $5.0 million.
-
Strategic Launches
Launched Niagen Plus telehealth platform and introduced NB4168, a lead pharmaceutical candidate for rare genetic diseases, receiving Rare Pediatric Disease and Orphan Drug designations.
-
Cautious 2026 Outlook
E-commerce expected to grow 10-15%, but ingredient business to decline further; Niagen Plus and skincare partnerships not expected to contribute meaningfully until 2027.
Analysis · NAGE · Life Sciences
Niagen Bioscience reported Q2 net sales of $29.8 million, missing the $30.7 million consensus, while net income collapsed to $1.0 million from $3.6 million a year ago as sales and marketing costs surged. The company launched a pharmaceutical program targeting rare genetic diseases and a telehealth platform, but the near-term financial picture is pressured by declining ingredient sales and rising expenses. The stock is trading near its 52-week low, and the earnings miss combined with a cautious outlook reinforces the negative sentiment.
How filings like this one have moved
In the 30 days to Oct 1, 2026, 36.1% of the 1051 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.56%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, NAGE was trading at $3.22 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $276.4M. The 52-week trading range was $3.12 to $11.29. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.